Stable, highly pure L-cysteine compositions for injection and methods of use
The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O 2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
1. A solution of L-cysteine comprising,
a pharmaceutically acceptable carrier, and
about 50 mg/mL of L-cysteine hydrochloride monohydrate, or
equivalent amount of a pharmaceutically acceptable L-cysteine or a salt or hydrate thereof;
wherein the solution is stored in a single-use vial;
wherein for at least 12 months from the time of manufacture of the solution, the solution will remain:
substantially free of visually detectable particulate matter,
at a pH from about 1.0 to 2.5, and
containing no more than 100 ppb of aluminum; and
wherein the solution is safe for use as an additive in a parenteral nutrition composition for intravenous administration to an individual for at least 12 months from the time of manufacture of the solution.
2. The solution of claim 1 , wherein the solution contains no more than 100 ppb of aluminum for at least 12 months from the time of manufacture of the solution when stored at about 25° C. and 60% relative humidity as shown by stability testing.
3. The solution of claim 1 , wherein the solution contains no more than 20 ppb fluoride and no more than 80 ppb iodide.
4. The solution of claim 2 , wherein the solution contains no more than 20 ppb fluoride and no more than 80 ppb iodide.
5. The solution of claim 1 , wherein the single-use vial is a silica-coated glass vial.
6. The solution of claim 2 , wherein the single-use vial is a silica-coated glass vial.
7. The solution of claim 1 , wherein the solution is substantially free of visually detectable particulate matter for at least 12 months from the time of manufacture of the solution when stored at about 40° C. and about 75% relative humidity as shown by stability testing.
8. The solution of claim 2 , wherein the solution is substantially free of visually detectable particulate matter for at least 12 months from the time of manufacture of the solution when stored at about 40° C. and about 75% relative humidity as shown by stability testing.
9. The solution of claim 1 , wherein upon dilution and admixture with a solution comprising one or more of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threononine, methoionine, tryptophan, alanine, arginine, glycine, proline, serine, and tryptophan, the resulting admixed composition is safe for intravenous administration for up to 24 hours after admixing.
10. The solution of claim 2 , wherein upon dilution and admixture with a solution comprising one or more of: leucine, isoleucine, lysine, valine, phenylalanine, histidine, threononine, methoionine, tryptophan, alanine, arginine, glycine, proline, serine, and tryptophan, the resulting admixed composition is safe for intravenous administration for up to 24 hours after admixing.
11. A method of preparing the solution of claim 1 comprising,
mixing at no more than 30° C. a pharmaceutically acceptable carrier comprising no more than 1 ppm dissolved oxygen with L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof;
adjusting the pH of said mixture to from about 1.0 to about 2.5;
transferring aseptically an amount of the pH-adjusted mixture into a single-use vial;
reducing the headspace oxygen in the single-use vial; and
sealing the single-use vial.
12. The method of claim 11 , wherein the headspace oxygen is reduced to about 1% or less by application of inert gas overlay and vacuum operation and without use of a lyophilizer.
13. The method of claim 11 , wherein the sealed single-use vial is not subjected to terminal sterilization.
14. The method of claim 11 , wherein the single-use vial is configured to substantially prevent atmospheric oxygen ingress and leaching of heavy metals and anions into the solution during storage of the solution in the vial.
15. A method of preparing the solution of claim 2 comprising,
mixing at no more than 30° C. a pharmaceutically acceptable carrier comprising no more than 1 ppm dissolved oxygen with L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof;
adjusting the pH of said mixture to from about 1.0 to about 2.5;
transferring aseptically an amount of the pH-adjusted mixture into a single-use vial;
reducing the headspace oxygen in the single-use vial; and
sealing the single-use vial.
16. The method of claim 15 , wherein the headspace oxygen is reduced to about 1% or less by application of inert gas overlay and vacuum operation and without use of a lyophilizer.
17. The method of claim 15 , wherein the sealed single-use vial is not subjected to terminal sterilization.
18. The method of claim 15 , wherein the single-use vial is configured to substantially prevent atmospheric oxygen ingress and leaching of heavy metals and anions into the solution during storage of the solution in the vial.
19. The solution of claim 1 , wherein for at least 18 months from the time of manufacture of the solution, the solution will remain:
substantially free of visually detectable particulate matter,
at a pH from about 1.0 to 2.5, and
containing no more than 100 ppb of aluminum; and
wherein the solution is safe for use as an additive in a parenteral nutrition composition for intravenous administration to an individual for at least 18 months from the time of manufacture of the solution.
20. The solution of claim 2 , wherein the solution contains no more than 100 ppb of aluminum for at least 18 months from the time of manufacture of the solution when stored at about 25° C. and 60% relative humidity as shown by stability testing.
21. The solution of claim 19 , wherein the solution contains no more than 20 ppb fluoride and no more than 80 ppb iodide.
22. The solution of claim 20 , wherein the solution contains no more than 20 ppb fluoride and no more than 80 ppb iodide.
23. The solution of claim 2 , wherein said individual is a neonate or infant requiring parenteral nutrition.
24. The solution of claim 20 , wherein said individual is a neonate or infant requiring parenteral nutrition.
25. The method of claim 12 , wherein the inert gas is argon or nitrogen.
26. The method of claim 16 , wherein the inert gas is argon or nitrogen.
27. The solution of claim 1 , wherein for at least 24 months from the time of manufacture of the solution, the solution will remain:
substantially free of visually detectable particulate matter,
at a pH from about 1.0 to 2.5, and
containing no more than 100 ppb of aluminum; and
wherein the solution is safe for use as an additive in a parenteral nutrition composition for intravenous administration to an individual for at least 24 months from the time of manufacture of the solution.
28. The solution of claim 2 , wherein the solution contains no more than 100 ppb of aluminum for at least 24 months from the time of manufacture of the solution when stored at about 25° C. and 60% relative humidity as shown by stability testing.
29. The solution of claim 28 , wherein said individual is a neonate or infant requiring parenteral nutrition.